Hyperbaric Oxygen Therapy as a Sole Agent Is Not Immunosuppressant in a Highly Immunogenic Mouse Model. (4th July 2010)

• Record Type: Journal Article
• Authors: Gassas, Adam; Min, Weixian; Evans, A. Wayne; Carter, Susan; Sándor, George K.; Grunebaum, Eyal
• Other Names: Zander Axel R. Academic Editor.
• Is Part Of: Bone marrow research. Volume 2011(2011)
• Publication Date: 2010-07-04
• Subjects: Bone marrow -- Periodicals; 616.41
• DOI: 10.1155/2011/579268
• Languages: English
• ISSNs: 2090-2999

Abstract

Abstract : Background . Hyperbaric oxygen (HBO) therapy, which is used for many conditions, may also have immunosuppressive effects and could be used for prevention or treatment of graft-versus-host disease (GvHD). If HBO is immunosuppressant, then we hypothesize that HBO therapy will delay the T-cell mediated skin graft rejection. Methods . C57/BL6 black-coated (H2B) mice received skin graft from CBA (H2D) white-coated mice. Mice were treated with either 19 session of 240 kpa oxygen or 29 session of 300 kpa oxygen, for 90 minutes. Mice were housed either 4 per cage or separately, to prevent friction and mechanical factors that may affect graft survival. Skin grafts were assessed daily. Results . There was no difference in length of graft survival between mice that received either regimens of HBO therapy and mice that did not receive HBO therapy. Conclusions . HBO therapy, as a sole agent, did not delay skin graft rejection in a highly immunogenic mouse model.